The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
Subscribe To Our Newsletter & Stay Updated
